ILYM21068 / EONHL1-20 / Friedberg
Research Question:
NA
Basic Study Information
Purpose:
The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability,
immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination
with lenalidomide and/or rituximab in patients with indolent NHL
Location: URMC WCI
Lead Researcher (Principal Investigator)
Lead Researcher:
Jonathan Friedberg, MD
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search